Dr. Laine has seven years of experience in consultative business development of enabling technologies supporting Pharmaceuticals and Biotechnology companies in their R&D and biomarker discovery efforts.
Prior to joining Diversigen, Dr. Laine has successfully held sales and business development positions with increasing responsibility for mid- to large-size companies focusing on Omics services across the pre-clinical and clinical pharmaceutical value chain. Dr. Laine was instrumental in the launch of various metabolite-based products in the United States, notably MetaMap©Tox, a database for early assessment/prediction of toxicity and MxP© Quality Control Plasma, an assay testing for pre-analytical errors occurring during plasma generation.
Dr. Laine received his PhD in Molecular Biology with a minor in Immunology and Physiology from the University Louis Pasteur in Strasbourg, France, in collaboration with the National Institute on Aging (NIA) in Baltimore, MD, USA. His Doctorate and Post-Doctoral resulted in 12 peer-reviewed publications and reviews on the regulation of gene expression and DNA repair in human and yeast cells.